The present paper reviews research in the area of the broad-spectrum chemot
herapeutic agent cisplatin (cis-diamminedichloro-platinum II) and examines
the implications for clinical neuropsychology arising from the neurological
disruption associated with cisplatin-based therapy. The paper begins with
a brief review of cisplatin treatment in terms other than survival alone, a
nd examines the side-effects and the potential central nervous system (CNS)
dysfunction in terms of neurological symptoms and concomitant implications
for neuropsychology. Two main implications for clinical neuropsychology ar
ising from cisplatin therapy are identified. First, cisplatin therapy impac
ts upon the psychological well-being of the patient, particularly during an
d in the months following treatment. It is suggested that during this time,
a primary role for neuropsychology is to focus upon the monitoring and the
active enhancement of the patient's social, psychological and spiritual re
sources. Second, with regard to neurocognitive changes, the review suggests
that (1) neurocognitive assessment may not yield stable results within 8 m
onths following treatment and (2) while perceptual, memory, attentional and
executive dysfunction may be predicted following cisplatin treatment, litt
le systematic research has been carried out to investigate such a possibili
ty. Future research might profitably address this issue and also specifical
ly examine the effects of low dosage cisplatin-based therapy and the effect
s of recently developed neuroprotective agents. Finally, there is some evid
ence to suggest that women may be more susceptible to neurotoxicity during
cisplatin therapy, but no gender-related cognitive effects are reported in
the cisplatin literature. Future research could usefully investigate gender
differences in association with cisplatin chemotherapy. Copyright (C) 2000
John Wiley & Sons, Ltd.